Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Rejects Sparlon Due To Single SJS Case; An Ominous Sign For Pharma?

Executive Summary

FDA's decision that Cephalon's attention deficit hyperactivity disorder treatment Sparlon is not approvable - based on an adverse event in a single patient - could be indicative of a more challenging regulatory environment for manufacturers

You may also be interested in...



Provigil Label: Panel’s “Not Recommended” Language Could Be Template

Language that specifically warns against using Cephalon's Provigil in pediatric patients should be added to the drug's labeling, FDA's Pediatrics Advisory Committee recommended Nov. 27

Provigil Label: Panel’s “Not Recommended” Language Could Be Template

Language that specifically warns against using Cephalon's Provigil in pediatric patients should be added to the drug's labeling, FDA's Pediatrics Advisory Committee recommended Nov. 27

FDA not rash in approving Nuvigil

Cephalon's Nuvigil (armodafinil) approved June 15 for excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy and shift-work sleep disorder. Approved labeling includes a bolded warning that a "serious rash requiring hospitalization and discontinuation of treatment" has been reported in patients using the product. The bolded warning adds that Nuvigil is not approved for use by children for any indication. A similar warning will be added to labeling for Cephalon's first-generation product Provigil (modafinil). Nuvigil had received an "approvable" letter in April 2006, with FDA requesting data on rashes in patients taking another modafinil-containing drug, Sparlon (1"The Pink Sheet" Aug. 21, 2006, p. 7)...

Related Content

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel